

Drug Monograph

Drug/Drug Class: **Lyrica® (pregabalin) oral solution/ Anticonvulsant/Analgesia**
Prepared for: MO HealthNet
Prepared by: Xerox Heritage LLC

New Criteria **Revision of Existing Criteria**

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Lyrica® oral solution contains 20 milligrams per milliliter of pregabalin.

Manufacturer: By: Pfizer Inc Kalamazoo, MI 49001

Indications: Lyrica® is indicated for treatment of neuropathic pain associated with diabetic peripheral neuropathy, fibromyalgia, neuropathic pain associated with spinal cord injury, postherpetic neuroalgia, adjunct therapy for adult patients with partial onset seizures

Costs: \$ 0.81 per mL of Lyrica® oral solution. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

Status Recommendation: Prior Authorization (PA) Required Open Access
 Clinical Edit PDL

Type of PA Criteria: Increased Risk of ADE Non-Preferred Agent
 Appropriate Indications Under Solicitation

Prepared By: Mary Jo Curtis, Pharm. D. candidate.
Date: November 12, 2012